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Abstract: Since the first description of patients with pneumonia of unknown origin in Wuhan in December 2019, 
unprecedented efforts of the international scientific community led to the identification and molecular characterization of 
its etiological agent, e.g. SARS-CoV-2. The global pandemic of COVID-19 represents an outstanding challenge for the 
scientists and medical professionals worldwide. In this review, we discuss the most important aspects of SARS-CoV-2 
biology and virology including antiviral and immunomodulatory treatment strategies as well as vaccine development. 
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INTRODUCTION 
A cluster of patients with pneumonia of unknown origin 
in Wuhan, Hubei province, China alerted the local 
medical community in December 2019.1 WHO China 
Country Office was informed about the cases on 31st 
December 2019.2 The causative pathogen was first 
isolated via inoculation of bronchoalveolar lavage fluid 
into human airway epithelial cells as well as Vero E6 
and Huh7 cell lines leading to the initial eight complete 
genome sequences of the 2019-new coronavirus.3, 4 The 
first genomic sequence of the virus (WH-Human_1) was 
published on January 10th 2020.5 On February 11th, the 
International Committee for the Taxonomy of Viruses 
(ICTV) Coronaviridae Study Group (CSG) recognized 
this virus as forming a sister clade to the prototype 
human and bat severe acute respiratory syndrome 
coronaviruses (SARS-CoVs) of the species Severe acute 
respiratory syndrome-related coronavirus and 
designated it as SARS-CoV-2.6 The disease caused by 
SARS-CoV-2 has been termed COVID-19 (coronavirus 
disease 2019) by the WHO.7 The epidemic potential of 
SARS-CoV-2 was recognized very early on. Although 
initial four COVID-19 patients reported association with 
Huanan Seafood Wholesale Market that was promptly 
closed, subsequent epidemiological analysis showed 
that only 1% of patients in China had a direct contact 
with the live-animal market trade suggesting the 
importance of person-to-person transmission in the 
spread of SARS-CoV-2 infection.8 In addition, the first 
report on SARS-CoV-2 transmission from infected 
asymptomatic persons described in Germany and China 
indicated early on that the control of this infection 
without preventive measures (prophylactic antiviral 
drugs or vaccines) will represent a major challenge for 
the global scientific community.9 Indeed, by March 11 
2020, COVID-19 had become a major global health 
concern and WHO declared the outbreak of SARS-CoV-
2 a global pandemic.10 A total of 38,141,034 SARS-
CoV-2 infections in 189 countries/regions as well as 
1,086,315 deaths from COVID-19 have been reported as 
of October 14th 2020.11  
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The aim of this review is to summarize the current 
knowledge on the most important features of SARS-
CoV-2 biology including basic virology, evolutionary 
origin of the virus and transmission potential. In 
addition, current approaches to antiviral and 
immunomodulatory treatment of the COVID-19 disease 




BIOLOGICAL FEATURES OF SARS-CoV-2 
Coronaviridae 
Zoonoses are human diseases wherein a causal agent is 
acquired from a vertebrate animal acting as an agent’s 
natural host.12 About 60% of emerging infectious 
diseases are zoonotic and about 25% are of viral origin.13 
Emerging viruses include viruses causing diseases in 
new hosts, appearing in new geographic areas, or both.14 
In humans, they are mostly zoonotic and many of those 
representing a significant burden to public health and 
global economy are spill-overs from natural wildlife 
reservoirs (e.g. primate, rodent, bird, bat or other 
mammal hosts) to humans.13 Diverse socio-economic, 
demographic, environmental and ecological factors are 
drivers of emerging infectious diseases including 
viruses.13, 15 Enlarging arable areas of land, 
deforestation, loss of biodiversity, hunting, outdoor 
recreational activities, global transport and travel, 
political instabilities and migrations can increase the 
likelihood of human contacts with wildlife reservoirs of 
new viruses.16 It was evident that the frequency of these 
events increased in the last two decades of the 20th 
century. Unfortunately, this trend continues into this 
century. Only in the last two decades, it has been 
underpinned with extremely serious viral disease 
outbreaks like Ebola, SARS and MERS. With the most 
recent emergence of COVID-19, we are witnessing a 
further increase of emerging and re-emerging viruses 
with the potential of changing the history of mankind.15 
The outbreaks of SARS in 2002, MERS in 2012 and 
COVID-19 in 2019 have etiological agents from the 
family Coronaviridae (https://talk.ictvonline.org/).17-19 
Before these three 21st-century outbreaks, coronaviruses 
had been considered etiological agents of serious 
diseases in animals, especially pigs, and only mild 
respiratory diseases in immunocompetent humans. The 
members of this viral family are widespread in nature 
and have natural animal, mostly mammal or bird, hosts. 
ICTV-CSG currently recognizes 39 species classified in 
27 subgenera, five genera and two subfamilies that 
belong to the family Coronaviridae, suborder 
Cornidovirineae, order Nidovirales, realm Riboviria.6 
There are presently seven members of Coronaviridae 
family, subfamily Coronavirinae, infecting humans. 
Four human coronaviruses (HCoV-NL63, HCoV-229E 
belonging to genus Alphacoronavirus plus HCoV-OC43 
and HKU1 belonging to Betacoronavirus genus) induce 
only mild upper respiratory diseases in 
immunocompetent hosts. However, some of them can 
cause severe infections in infants, young children and 
elderly people.20 The three highly pathogenic viruses for 
humans clustering within the Betacoronavirus (β-CoV) 
genus are SARS-CoV, MERS-CoV and the emerging 
virus first tentatively named 2019-nCoV then officially 
renamed SARS-CoV-2 by the ICTV-CSG.6 The 
nomenclature of SARS-CoV-2 is based on its genome 
characteristics as reflected in its taxonomical position 
within viral species Severe acute respiratory syndrome-
related coronavirus, genus Betacoronavirus, subgenus 
Sarbecovirus.6, 21 All members of the family 
Coronaviridae form enveloped roughly spherical 
particles of 100-160 nm in diameter encasing a positive-
sense, single-stranded RNA (+ssRNA) genome of 27-32 
kb in size (Figure 1). The 5'-terminal two-thirds of the 
of 29.903-nucleotides-long SARS-CoV-2 genome 
encode a polyprotein 1a/1ab whose protein products are 
directly translated from the genomic RNA and cleaved 
by virus proteases.21 The cleavage products, especially 
the viral RNA dependent RNA polymerase (RdRp) and 
the proteins forming the replication-transcription 
complex, are essential for the genome transcription and 
replication. This part of the genome also encodes 16 
non-structural proteins.22 In such a large +ssRNA viral 
genome, there is a large number of accessory genes 
specific for virus species but probably dispensable for 
some steps in the viral cycle.20 The replication-
transcription complex also enables the discontinuous 
synthesis of a number of subgenomic RNA molecules 
from the 3’-terminal third of the genome via –ssRNA 
intermediates. The production of subgenomic RNAs 
whose templates are nested within the genome came to 
define the superfamily Nidovirales (lat. nidus = nest) 
comprising a number of other virus families. The 3’- 
terminal part of the viral genome encodes structural 
virion components: envelope spike glycoproteins (S), 
envelope (E), membrane (M) and nucleocapsid (N) 
proteins. Besides these main virion components, several 
accessory proteins are produced.21, 22 Although the 
function(s) of many of these proteins have yet to be 
determined, principal players and the steps of the viral 
cycle have been inferred from the similarities with other 




ORIGINS OF SARS-CoV-2 
The SARS epidemic, as one of the most important public 
health threats in the 21st century, prompted research 
revealing bats as the reservoir hosts of many SARS-like 
coronaviruses.24 Whilst the human-infecting 
coronaviruses HCoV-OC43 and HCoV-HKU1 probably 
originated from rodents,20, 25 the rest of them (HCoV-
NL63, HCoV-229E, SARS-CoV, MERS-CoV) have a 
presumed bat origin.20, 25-30 According to the available 
research data, the same applies to the latest SARS-CoV-
2.21, 31, 32 As the current number of SARS-CoV-2 fully  
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Figure 1. a) schematic representation of SARS-CoV-2 virion and its genome, b) non-structural proteins coded in orf1ab and orf1a, b) virus 
enters host cell via ACE2 receptor. 
 
 
sequenced genomes is constantly rising, the comparative 
analyses of the viral genome support the natural origin 
of the virus, and there is no credible evidence to believe 
otherwise.33 Insectivorous Chinese horshue bats (family 
Rhinolophidae) are pinpointed as particularly interesting 
group in the search for SARS-like coronavirus 
progenitors.31, 34 They can host different virus species 
and different viral populations within a species 
(quasispecies) facilitating recombination and the 
emergence of new virus variants and species.29, 30 It is 
still early to know whether this originally bat virus 
preadapted to humans in another animal species like 
pangolin, or whether the zoonotic transfer was enabled 
by adaptive process in humans.31, 34 Data about the 
genome sequence and specific genetic similarities and 
differences between SARS-like coronaviruses should 
help in the understanding of zoonotic transfer and help 
prevent future zoonotic events. 
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DISCOVERY AND DESCRIPTION OF SARS-
CoV-2 
Current understanding of SARS-COV-2 stems from 
data obtained in the initial studies that analyzed patients’ 
samples in the first few weeks after the epidemic event 
was recognized (end of January/ beginning of February).  
Lu et al. conducted research on samples from nine 
patients connected to the Huanan Seafood Market.4 
Common respiratory pathogens were excluded using 
commercially available kits, while previously published 
essays were used for the exclusion of SARS-CoV and 
MERS-CoV infection. Human airway epithelial cells 
were used for inoculation with bronchoalveolar lavage 
fluids or throat swabs from the patients in order to isolate 
a virus. Viral genomes were then sequenced using 
combinations of Sanger sequencing, high throughput 
sequencing on BGI, Illumina and Nanopore platforms, 
and the addition of rapid amplification of cDNA ends 
for terminal sequences. Phylogenetic analysis using the 
complete genome sequence showed that the new virus 
has the highest similarity with bat SARS-like 
coronaviruses: bat-SL-CoVZC45 and bat-SL-
CoVZXC21 (87.99 % and 87.23 %, respectively). The 
lowest sequence identity based on specific coding 
regions between analyzed virus and bat SARS-like 
coronaviruses was detected for S gene (75 %). It was 
also shown that the new virus has relatively low 
genomic similarity to SARS-CoV (79%) and MERS-
CoV (50%). Genomic organization was predicted to be 
similar to those of bat SARS-like coronaviruses and 
consisted of 12 open reading frames that code for 
proteins similar in length to those of bat viruses with the 
exception of spike protein. Spike protein, which has two 
basic domains: S1 and S2 in all Coronaviridae 
members, showed higher similarity when using receptor 
binding domain for comparison with SARS-Cov than 
with bat-SL-CoVZC45 and bat-SL-CoVZXC21. Such 
results suggested that novel virus can use angiotensin-
converting enzyme 2 (ACE2) receptor on human cells as 
an entry point.4 
In the same month, Zhu N et al. (2020) reported findings 
based on the analysis of lower respiratory tract samples 
from 3 patients.35 Patients whose samples were analyzed 
were connected to the Huanan Seafood Market, and 
diagnosed with pneumonia of unknown cause. After 
exclusion of 18 common viruses and 4 bacteria using 
commercial diagnostic tests, high throughput 
sequencing using Illumina and Nanopore platforms was 
conducted in order to describe the viral genome and 
conduct phylogenetic analysis. Obtained genome 
sequences showed 86.9% similarity with the previously 
described bat SARS-like CoV genome and were 
relatively dissimilar to SARS-CoV and MERS-CoV 
genomes. Additionally, real-time PCR for the detection 
of the pan β-CoV RNA dependent RNA polymerase 
(RdRp) region confirmed that the new virus belongs to 
the family of RNA viruses, Coronaviridae. Virus 
particles were also visualized using transmission 
electron microscopy analysis of human airway epithelial 
cells infected with the virus. Spherical particles with 
spikes 9 to 12 nm that resembled solar corona were 
observed.35  
Zhou P et al. (2020) analyzed samples from seven 
patients with severe pneumonia, mostly workers at 
seafood market, in order to find the cause of the 
symptoms.36 Pan-CoV PCR primers were used as a first 
step and five positive samples were further investigated 
using high throughput sequencing, de novo assembly 
and targeted PCR. The genome of the new virus 
consisted of 6 open reading frames characteristically 
found in coronaviruses, as well as additional accessory 
genes. Although nucleotide sequences of most open 
reading frames showed less than 80 % similarity with 
corresponding open reading frames of SARS-CoV, 
replicase conserved domains within RdRp from 
ORF1ab had 94.4 % match with the one from SARS-
CoV when amino acid sequences were compared. High 
sequence similarity between novel virus and bat SARS-
like coronavirus RaTG13 was found based both on full-
length genome and the RdRp and spike genes. 
Furthermore, the authors conducted infectivity study 
using HeLa cells that expressed human, Chinese 
horseshoe bat, civet, pig and mice ACE2 proteins. The 
novel virus was able to enter the human cells using all 
but mouse ACE2 receptors, and it did not use other 
known corona virus receptors.36 Further studies 
confirmed interaction of the spike protein and ACE2 
receptor.37-39  
Data published in first few months after the outbreak 
were later confirmed and showed that SARS-CoV-2 is a 
+ss RNA virus that has 14 ORFs encoding 27 proteins, 
as was mentioned earlier (Figure 1a). Its 5’-terminus 
harbors open reading frame orf1ab and orf1a. These orfs 
contain 15 non-structural proteins (nsps) among which 
are nsp12 and nsp14 (Figure 1b). Nsp12 is a RdRp that 
has a pivotal role in the viral life-cycle, lacks host 
homologues and has a high level of sequence and 
structural conservation which makes it an optimal target 
for therapeutics.40 However, there has been remarkably 
little biochemical characterization of nsp12 and a lack of 
fundamental data to guide the design of antiviral 
therapeutics and study their mechanism of action. A 
promising class of RdRp inhibitors are nucleoside 
analogues (NAs), small molecule drugs that are 
metabolized intracellularly into their active 
ribonucleoside 5'-triphosphate (RTP) forms and 
incorporated into the nascent viral RNA by error-prone 
viral RdRps. This can disrupt RNA synthesis directly via 
chain termination or lead to the accumulation of 
deleterious mutations within the viral genome. 
However, the post-replicative repair capacity provided 
by the nsp14 exonuclease (ExoN) that is essential for 
maintaining the integrity of the large ~30 kb genomes of 
coronaviruses reduces the antiviral effects of certain 
NAs. Despite this, several NAs are currently being used 
for the treatment of other viral infections and have been 
identified as potential anti-CoV candidates.40 The 3’-
terminus of SARS-CoV-2 genome harbors structural 
genes (spike (S), envelope (E), membrane (M), and 
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nucleocapsid (N) genes) and some accessory genes.41 As 
mentioned earlier, the spike gene is recognized as the 
viral genome sequence with the highest genetical 
similarity to SARS-CoV and has therapeutic value 
because of its function – binding to human cell receptor 




As SARS-CoV-2 is a virus that mainly targets upper 
respiratory pathways (and lungs), similarly to SARS-
CoV and MERS-CoV, it is supposed that they share the 
same main pathway of transmission through droplets 
released by coughing or sneezing that remain in the air 
or on the surrounding surfaces. A healthy individual can 
be infected by inhaling the aerosol containing the viral 
particles or through direct contact between mucous 
membranes in the nose and mouth and infected 
surfaces.42, 43  
It remains unclear whether mucous membranes in eyes 
could also be exploited as an entrance point by 
respiratory viruses, as there are conflicting reports 
regarding the presence of SARS-CoV in samples of tears 
collected from infected individuals44-46, as well as 
SARS-CoV-2.47,48 Still, the lack of eye protection was 
associated with an increased risk of SARS-CoV 
transmission from infected patients to health care 
workers during the 2003 Toronto SARS outbreak49 and 
is assumed to be the reason why a Chinese respiratory 
specialist was infected with SARS-CoV-2 in January 
2020 despite wearing a protective suit and N95 
respirator.50 
A smaller percentage of patients (2-10%) diagnosed 
with SARS-CoV-2 displayed gastrointestinal 
symptoms, such as diarrhea or abdominal pain, 
alongside respiratory symptoms. Moreover, in some 
cases, it was observed that the gastrointestinal 
symptoms had developed before fever and respiratory 
symptoms.51 Also, it is known that ACE2, a membrane 
receptor through which SARS-CoV-2 enters lung 
cells52, is also expressed on the cells of intestinal tract, 
mostly in the glandular cells of gastric, duodenal, and 
rectal epithelia.53 It has not yet been established that 
gastrointestinal symptoms in mentioned cases are 
caused by SARS-CoV-2, nor has it been confirmed yet 
that fecal–oral transmission is another means by which 
SARS-CoV-2 is spread. However, the virus has been 
detected in the faeces53, as have both SARS-CoV and 
MERS-CoV54, 55, so it is possible that SARS-CoV-2 
could also be transmitted this way.  
Viral RNA has also been detected in plasma or serum of 
15% of the first Wuhan SARS-CoV-2 patients, but at 
very low concentrations, regardless of the severity of the 
symptoms.56 Therefore, the possibility of transmission 
of the virus through blood donations cannot be 
overlooked, with donations by asymptomatic carriers 
posing the greatest danger. However, blood collection 
establishments are not currently under obligation to 
undertake any specific SARS-CoV-2-related actions, 
since there are no data suggesting a risk of transfusion 
transmission of SARS-CoV-2.57, 58 A case report from 
South Korea described a 21-year-old man diagnosed 
with very severe aplastic anemia in November 2019 who 
received a platelet transfusion from a SARS-CoV-2 
infected individual who displayed no symptoms at the 
time of the donation. The recipient was tested multiple 
times for SARS-CoV-2 post transfusion; all the results 
were negative.59 
There has been no evidence of vertical transmission of 
SARS-CoV-2 from mother to child during childbirth or 
through breastmilk so far. Zhu H et al. (2020) examined 
samples taken from amniotic fluid, umbilical cord blood 
and throat swabs of babies born to SARS-CoV-2 
positive mothers immediately after delivery, as well as 
milk samples60, while Chen H et al. (2020) examined 
only throat swabs of newborns.61 No sample in either 
study tested positive for SARS-CoV-2. A case study by 
Chen S et al. examined placentas of three women with 
diagnosed SARS-COV-2 infection during pregnancy. 
The viral RNA was not detected in newborns, and the 
placentas displayed no histopathological changes 




SARS-CoV-2 was shown to remain viable in aerosols 
for three hours, with a reduction in infectious titer 
similar to SARS-CoV in the same conditions. Both 
viruses displayed longest viability on stainless steel and 
plastic, and viable SARS-CoV-2 was detected up to 72 
hours after application to these surfaces, though its 
estimated half-life is considerably shorter (around six 
and seven hours respectively).63 Chin et al. (2020) found 
that no infectious SARS-CoV-2 could be detected on 
stainless steel and plastic only on day 7. Infectious virus 
could not be found on glass and banknotes after four 
days, which is a considerably longer period of 
incubation compared to printing and tissue papers (three 
hours)64, copper (four hours), cardboard (24 hours)63, or 
even wood and cloth (two days)63 at room temperature 
and 40-60% relative humidity. The estimated half-life of 
the virus in aerosol and on copper was about an hour, 
around four on cardboard63 and five hours on glass64 
while it was somewhat longer on banknotes (around 
eight hours).64 These results suggest that SARS-CoV-2 
remains viable on smooth surfaces considerably longer. 
A detectable level of infectious virus could still be 
present on the outer layer of a surgical mask even after 
a week.64 
SARS-CoV-2 is highly stable at 4°C but sensitive to 
heat, and the time for its inactivation is gradually 
reduced upon the temperature increase. It also remains 
viable in a wide range of pH values at room temperature. 
On the other hand, no infectious virus could be detected 
after 5-minute incubation at room temperature in various 
disinfectants, which suggests that the virus is susceptible 
to standard disinfection methods.64 
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CURRENT APPROACHES TO ANTIVIRAL 
THERAPY AND VACCINATION 
SARS-CoV-2 infection in humans and development of 
coronavirus disease COVID-19 
Clinical presentations of SARS-CoV-2 infection exhibit 
a broad spectrum of severity and progression patterns, 
ranging from asymptomatic infection to mild, severe or 
critical COVID-19 disease.65 The most commonly 
reported signs and symptoms of COVID-19 include 
fever, dry cough, fatigue, myalgia, chest tightness and 
pain, sore throat, shortness of breath, dyspnea, 
rhinorrhea etc. Although the main target for SARS-
CoV-2 infection are the lungs, distribution patterns of 
SARS-CoV-2 receptor ACE2 in various tissues and 
organs are associated with damage to the cardiovascular, 
gastrointestinal and central nervous systems observed in 
COVID-19.66 Initial clinical symptoms sub-acutely 
progress to respiratory distress and acute respiratory 
distress syndrome (ARDS) in about 8-19% of patients 
(depending on age, sex, genetics and comorbidities) 
with about 14% of patients requiring supplemental 
oxygen and approximately 5% needing mechanical 
ventilation.66  
The hallmark of severe COVID-19 pathogenesis is the 
hyperactivation of the immune response to SARS-CoV-
2 that includes massive infiltration of activated 
monocytes, macrophages and lymphocytes into the 
pulmonary interstitium that is, in addition to vasculitis 
and hypercoagulability, associated with development of 
ARDS.67 Increased synthesis of high concentrations of 
proinflammatory cytokines and biological response 
modifiers including IL-1, IL-2, IL-6, IL-7, IL-10, TNF-
α, granulocyte colony stimulating factor, interferon 
(IFN)-γ inducible protein-10 (IP-10), monocyte 
chemoattractant protein-1 (MCP-1), and macrophage 
inflammatory protein 1-α (MIP1-α) in response to 
SARS-CoV-2 infection, which is often referred to as a 
“cytokine storm”, plays a central role in COVID-19 
pathogenesis and is associated with multiple organ 




Antiviral and immunomodulatory treatment strategies 
in COVID-19 
Current therapeutic strategies in COVID-19 include 
supportive care and broad-spectrum antibiotics, 
supplemented initially by antiviral drugs intended to 
inhibit SARS-CoV-2 replication and followed by 
immunomodulatory drugs aimed at inhibiting the 
immune system.68 Recent studies on SARS-CoV-2 
molecular virology provided an excellent scientific 
background for the repurposing of existing antiviral 
drugs for the treatment of COVID-19. Currently used 
antiviral drugs that inhibit key steps in the SARS-CoV-
2 replication cycle include entry inhibitors (receptor-
binding, fusion and endosomal-acidification inhibitors), 
RdRp inhibitors (nucleoside and nucleotide analogues) 
and 3CL protease inhibitors.69, 70 So far, several direct 
acting antiviral drugs (umifenovir, remdesivir, 
favipravir, lopinavir/ritonavir, chloroquine phosphate 
and hydroxychloroquine) have been considered by 
international or national regulatory agencies 
(recommended for authorization, approved for 
emergency use, approved or retracted from clinical use) 




Umifenovir is a viral entry inhibitor that interferes with 
the fusion of the viral envelope and cell membrane by 
interfering with clathrin-mediated endocytosis.71-73 In 
vitro, umifenovir inhibits SARS-CoV-2 replication in 
Vero cells by blocking or impeding the trimerization of 
the viral S glycoprotein that is crucial for the viral 
adherence step.74, 75 This small indole derivative is 
approved for clinical use as prophylaxis and treatment 
of influenza in Russia and China and has been approved 
for the treatment of COVID-19 in China based on 
mainly retrospective national studies.76-78  
Chloroquine phosphate and its derivative 
hydroxychloroquine are aminoquinolines that have been 
traditionally used for the prophylaxis and treatment of 
malaria and for the treatment of various autoimmune 
diseases. Both molecules exhibit antiviral activity; 
chloroquine phosphate inhibits phosphorylation of the 
SARS-CoV-2 receptor by interfering with the viral 
binding to the receptor, while hydroxychloroquine 
increases pH within the endosomes, inhibits endosome-
lysosome fusion and prevents the release of viral 
molecules into targets cells. In addition, 
hydroxychloroquine is an immunomodulator that 
interferes with macrophage activation and cytokine 
synthesis. Since hydroxychloroquine is metabolized into 
chloroquine, both mechanisms of antiviral activity are 
expected to be observed in vivo. Both molecules exhibit 
antiviral activity against several RNA viruses including 
SARS-CoV, MERS-CoV and SARS-CoV-2 in vitro.79 
Despite the encouraging early results from clinical trials 
conducted in China and the subsequent approval of the 
drug by the Chinese medical authorities, results of a 
retrospective multicenter cohort study of 1438 
hospitalised COVID-19 patients showed that treatment 
with hydroxychloroquine and/or azithromycin failed to 
influence mortality compared to placebo.80-81  
Chloroquine phosphate and hydroxychloroquine are by 
far the most controversial drugs used in COVID-19 
pandemic, not only because of the public non-expert 
endorsement of their prophylactic uses but also because 
of the retraction of the largest clinical study published in 
Lancet by Mehra et al. (2020) due to the inability of the 
authors to validate the primary data source 
(multinational registry of 96,032 patients collected by a 
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Table 1.  Selected antiviral drugs used for the treatment of COVID-19 disease 
Name  
Antiviral drug class 
and mechanism of 
action 
Antiviral activity in vitro 
and in vivo 
Previous clinical research/use, current approval status and 
selected clinical data for COVID-19 treatment 
Umifenovir 
- entry inhibitor  
- blocks trimerisation of 
  viral S glycoprotein 
In vitro: SARS-CoV-2; 
influenza virus A, influenza 
virus B, Ebola virus, Lassa 
virus, HBV, HCV, HHV-8, 
VZV, polioviruses  
- approved for treatment of influenza (China, Russia) 
- approved for COVID-19 treatment (China, 2020) 
 
- shorter time to viral clearance compared with 
  lopinavir/ritonavir arm (n=50 patients)78 
- higher reduction in mortality in the umifenovir arm  
  compared with lopinavir/ritonavir or oseltamivir arms77  
Remdesivir  
- RdRp inhibitor 
(adenosine analogue) 
In vitro: SARS-CoV-2, 
SARS-CoV, MERS, CoV, 
HcoV-OC43, HcoV-229, 
Ebola virus, Marburg virus, 
Parainfluenza type 3 virus, 
Nipah virus, Hendra virus, 
measles virus, mumps virus, 
RSV 
In vivo: MERS-CoV 
- discouraging results of the Ebola clinical trial86 
- recommended by EMA for authorisation in the European  
  Union for COVID-19 treatment (June 25th, 2020)87 
- emergency use authorisation by the FDA in COVID-19  
  (May 1st, 2020) 
 
- reduction in time to recovery from severe COVID-19  
  compared with placebo and numerically lower mortality rate 
  in the remdesvir group (open-label, phase 3, randomised  




In vitro: SARS-CoV-2, 
influenza viruses, Ebola 
virus, Lassa virus, Yellow 
Fever virus, Chikungunya 
virus, noroviruses and 
enteroviruses  
- approval for new or re-emerging influenza in Japan (2014) 
- a trend towards improved survival in proof-of-concept Ebola  
  trial92 
- approved for COVID-19 treatment in Russia, China and 
  India 
 
- shorter times to SARS-CoV-2 negative RNA assay, mean  
  time of antipyretic use and cough remission time were  
  reported in the favipravir versus umifenovir group but failure 
  to demonstrate between-group differences in the primary end  
  point defined as clinical improvement by day 7 did not differ  
  (randomized clinical trial)94 
- better treatment effect in terms of disease progression  
  (radiological assessment) and time to viral clearance of  
  favipravir compared with a combination of lopinavir and  
  ritonavir (IFN-alpha was administered to both groups via  
  aerosol inhalation) in patients with moderate or mild  
  COVID-1993  
Lopinavir and 
ritonavir 
Protease inhibitor and 
cytochrome CPY3A4 
inhibitor 
In vitro: HIV-1, SARS-CoV-
2, SARS-CoV 
In vivo: HIV-1, SARS-CoV 
- approved for the treatment of HIV-1 infection 
- therapeutic option for COVID-19 in China 
 
- 19 clinical trials in COVID-19 patients failed to confirm 
  clinical efficacy 
- no benefit of lopinavir/ritonavir beyond standard-of-care  
  treatment (randomised, open-label clinical trial, n=199  





- inhibition of ACE2  
  phosphorylation, 
  increase in the 
  endosomal pH 




- approved for prophylaxis, the treatment of malaria and the  
  treatment of autoimmune diseases 
- approved for COVID-19 treatment in China 
 
- chloroquine use associated with reduction of symptom  
  duration and prevention of pneumonia exacerbation in  
  COVID-19 patients compared to controls (n=100 patients)80 
- treatment with hydroxychloroquine and/or azithromycin  
  failed to influence mortality compared to placebo  
  (retrospective multicenter cohort study, n=1438 hospitalised  
  COVID-19 patients)81 
Legend: hepatitis C virus (HCV), hepatitis B virus (HBV), human herpesvirus-8 (HHV-8), vesicular stomatitis virus (VZV), respiratory syncytial virus 




Remdesivir is a phosphoramidate adenosine 
(nucleotide) analogue that acts as delayed chain 
terminator and inhibits RdRp of various RNA viruses. It 
is a direct-acting antiviral molecule that incorporates 
into nascent viral RNA, resulting in premature 
termination of the viral RNA synthesis.84 Remdesivir is 
a pro-drug that is metabolized within cells into an 
alanine metabolite by a sequence of hydrolytic steps that 
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start with esterase-mediated hydrolysis of a 
phosphoramidate carrier into a monophosphate 
derivative and, subsequently, into an active 
triphosphorylated analogue of adenosine by intracellular 
nucleoside-phosphate kinases. Remdesivir exhibits 
antiviral activity against human and animal 
coronaviruses including SARS-CoV, MERS-CoV, 
SARS-CoV-2,   HcoV-OC43   and   HcoV-229 in 
vitro.79, 84, 85 Despite discouraging results of the clinical 
trial in Ebola patients conducted in Congo, remdesivir 
was proven to be safe for use in humans and 
subsequently immediately entered clinical trials for 
COVID-19.86 On June 25th 2020, remdesivir become 
the first COVID-19 therapeutic option recommended by 
European Medicinal Agency (EMA) for authorization in 
the EU for the treatment of patients with pneumonia who 
require supplemental oxygen therapy.87 The 
recommendation was mainly based on the results of an 
open-label, phase 3, randomized controlled US National 
Institute of Allergy and Infectious Diseases (NIAID)-
ACTT-1 clinical trial of 1063 patients that reported 
reduced time to recovery from severe COVID-19 
associated with remdesivir treatment compared to 
placebo (11 vs. 15 days).88 
Favipravir is a pyrazinecarboxamide derivative and 
guanosine analogue that inhibits viral replication via 
competitive inhibition of viral RdRp as well as by 
induction of lethal RNA transversion mutations 
resulting in a non-viable viral phenotype.89 Shannon et 
al. (2020) showed a 12-fold increase in G-to-A and C-
to-U transition mutations in SARS-CoV-2-infected 
Vero cells cultivated in the presence of favipravir 
leading to a further reduction in the already low cytosine 
content (17.6%) of the viral genome.90 Increased 
mutation frequency was associated with a high diversity 
of viral variants in favipravir-treated infected cells as 
well as with a reduction of virus-induced cytopathic 
effect, reduction of viral load and lower virion yield.90 
Favipravir is a pro-drug that is metabolised into its 
active form favipiravir-ribofuranosyl-5'-triphosphate 
(favipiravir-RTP) by human hypoxanthine guanine 
phosphoribosyl-transferase. In vitro, favipravir can 
inhibit the replication of a wide range of RNA viruses 
including influenza viruses and SARS-CoV-2.75, 91 Prior 
to COVID-19 pandemics, clinical use of favipravir has 
been limited to the treatment of non-seasonal influenza 
in Japan (since 2014). In addition, favipravir showed a 
trend towards improved survival in Ebola patients 
treated in a clinical trial carried out in Guinea.92 Based 
on the results from COVID-19 clinical experience and 
trials conducted in China and Russia, favipravir become 
the first approved antiviral drugs for COVID-19 
treatment in China (March 2020) and, more recently, in 




The majority of data on COVID-19 treatment using 
protease inhibitors comes from clinical trials employing 
a combination of lopinavir (inhibitor of HIV-1 aspartyl 
protease) and ritonavir (cytochrome CYP3A4 enzyme 
inhibitor), which is used to increase the bioavailability 
of lopinavir. Although coronaviruses encode a different 
class of proteases (cysteine protease), in vitro data 
suggest that the lopinavir/ritonavir combination might 
inhibit coronavirus 3CL1pro protease. Despite initial 
encouraging results from China on the use of 
lopinavir/ritonavir in combination with ribavirin and 
confirmed antiviral activity against SARS-CoV-2 in 
vitro, more than 19 clinical trials in COVID-19 failed to 
confirm clinical efficiency of this therapeutic 
regiment.98-100 Nevertheless, lopinavir/ritonavir 
combination remains an approved therapeutic option for 
the treatment of COVID-19 in China. 
 
 
Innovative approaches to antivirals 
The majority of innovative approaches in antiviral 
therapy of COVID-19 are focused on entry inhibitors 
targeting the ACE2 receptor. Since unselective 
inhibition of ACE2 could induce alterations in the 
ACE2/angiotensin-1 to -7/Mas axis and its anti-
inflammatory effect, recombinant human ACE2 
molecule that could bind to virions prior to their 
attachment to target cells is explored as a possible entry 
inhibitor. Monteil et al. (2020) showed that recombinant 
human ACE2 inhibits SARS-CoV-2 replication in 
cellular and embryonic stem-cell derived organoids by 
1,000-5,000-fold, providing a scientific foundation for 
the further development of this inhibitor.101 In addition, 
a new generation of entry inhibitors focus on host 
proteins important for the initial stage of SARS-CoV-2 
replication, such as TMPRSS2 and CatB/L.102 Inhibition 
of viral protein nuclear transport represents another 
potential therapeutic strategy for RNA viruses.103 
Recently, Caly et al. (2020) showed that the anti-
parasitic drug ivermectin reduces SARS-CoV-2 
replication in vitro, opening a possibility for the 
repurposing of the drug for COVID-19 as well.104   
 
 
Immunomodulators in COVID-19 
Numerous specific and non-specific 
immunomodulatory drugs/treatments have been 
employed for COVID-19 treatment including: 
convalescent plasma, corticosteroids (dexamethasone), 
cytokine receptor antagonists targeting IL-6 and IL-1 
(anakinra, tocilizumab, sarilumab, siltuximab), growth 
factor inhibitors targeting granulocyte-macrophage 
colony-stimulating factors (gimsilumab, lenzilumab, 
namilumab) and vascular endothelial growth factor 
(bevacizumab), JAK inhibitors (baricitinib, ruxolitinib), 
macrolides (azithromycin) and interferons (recombinant 
IFN- α2a, IFN-α2b, IFN-β1a and IFN-β1b) with variable 
rates  of success   (selected data presented  in Table 
2).105-110  Innovative  approaches to  immunomodulation  
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Table 2. Selected immunomodulatory therapeutic strategies in COVID-19 
Name  Drug class Mechanism of action 
Previous clinical research/use, current approval status and selected 
clinical data for COVID-19 treatment 
Dexamethasone corticosteroid 
- inhibition of  
  proinflammatory  
  signals via binding to 
 the glucocorticoid  
 receptor  
- a variety of inflammatory and autoimmune diseases 
 
- 10-day dexamethasone treatment (randomised clinical trial, n=6425)108 
- 28-day mortality reduced with dexamethasone in the overall cohort  
  (21.6% vs 24.6% usual care; p<0.001) 
- reduced mortality by 35% in those on mechanical ventilation (29.0% vs.  
  40.7%; p = 0.003), and by 20% in those treated with oxygen  





- antiviral activity 
  (neutralising 
  antibodies) 
- immunomodulatory 
  activity 
- historical clinical use with variable results (SARS-CoV, MERS-CoV, 
  Ebola virus, influenza viruses) 
- August 23rd 2020, Emergency Authorisation use by the FDA 
 
- encouraging results from case reports, case series and preliminary results  
  of clinical trials and expanded access programmes (few completed) 
- significant reduction in mortality within 28 days in COVID-19 patients  
  receiving convalescent plasma107 
- preliminary non-peer reviewed results105 showed significantly lower 7-day 
  mortality rate in patients transfused early (within 3 days of diagnosis)  
  compared with patients transfused 4 or more days after diagnosis (8.7%  
  vs. 11.9%, p<0.001), similar observations for 30-day mortality and for  






for IL-6 receptor 
- inhibition of IL-6 
  mediated signalling and 
  biological activity 
- approved for the treatment of rheumatoid arthritis, systemic juvenile  
  idiopathic arthritis, cytokine release syndrome 
 
- observational, retrospective cohort study recently showed a trend 
  association towards reduced mortality among COVID-19 patients treated 
  with tocilizumab at the intensive care unit.106 
 
 - a prospective series of 100 hospitalised COVID-19 patients with 
   pneumonia and ARDS requiring ventilatory support showed significant  
   clinical improvement upon tocilizumab treatment.109  
Legend: interleukin-6 (IL-6), acute respiratory distress syndrome (ARDS), coronavirus disease 2019 (COVID-19) 
 
 
in COVID-19 include the use of stem cell-derived NK-
cells (currently used in oncology) that might boost 
innate antiviral immune responses, as well as 
mesenchymal stem cell therapy that restores endothelial 
permeability and exhibits anti-inflammatory activity.111 
  
 
Traditional Chinese Medicine (TCM) 
Since the beginning of the pandemics in Wuhan, self-
made or commercially available TCM (reviewed by 
Yang et al. 2020) has been used for COVID-19, alone or 
in combination with conventional antiviral drugs.112 By 
February 2020, TCM has been used in 60,107 confirmed 
COVID-19 patients (estimated 85.2% of total confirmed 
cases in China within that time period).112   
Antiviral (inhibition of 3Clpro, RdRp and inhibition of 
S protein interaction with ACE2) and 
immunomodulatory (reduction of cytokine synthesis) 
properties of TCM documented in vitro and in animal 
models as well as favorable clinical effects documented 
in SARS-CoV epidemic, make TCM an important 
COVID-19 treatment option in China. However, the 
clinical effect of TCM is currently difficult to interpret 
due to the lack of randomised or placebo-controlled 
clinical trials. 
SARS-CoV2 vaccine development 
The availability of COVID-19 genome sequences and 
previous experience in the development of candidate 
vaccines for SARS-CoV and MERS-CoV contributed to 
the rapid development of 145 candidate SARS-CoV-2 
vaccines, with 34 of them undergoing clinical evaluation 
(updates available by the WHO).113  
The “ideal” vaccine is expected to induce a strong 
humoral immune response based on long-lasting 
neutralizing antibodies as well as specific T-cell 
immunity, but other parameters such as safety and 
manufacturing and logistical challenges have to be 
carefully evaluated.114 The most promising SARS-CoV-
2 vaccines are focused on protein subunit (54 
candidates) and nucleic acid (37 candidates) 
technologies, but other vaccine development strategies 
are likely to play an important contribution as well.113 
Currently there are seven main vaccine development 




DNA vaccines are based on plasmid DNA encoding one 
or several viral antigens (S, M or N) that are expressed 
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in host cells.114, 115-117 The synthesized protein induces 
the MHC class I pathway leading to cell mediated 
immune response, or it is released outside of the host cell 
where it acts as an exogenous antigen presented by 
MHC class II pathway to the CD4+ T-cells, leading 
subsequently to the induction of humoral immunity.118 
Some of the candidates have already been demonstrated 
to activate both humoral and cell mediated immune 
response against SARS-CoV-2 in nonhuman primates, 
guinea pigs and transgenic mice.116, 119 DNA vaccines 
that are currently in clinical trials are focused on S 
glycoprotein but differ in the approach to the plasmid 
delivery (electroporation for the INO-4800 vaccine or a 
hybrid transporter protein within live Bifidobacterium 
longum by the bacTRL-Spike vaccine).116, 117 
Nevertheless, no DNA vaccine has been approved for 
use in humans so far. Possible challenges for this type of 
vaccines include efficacy of plasmid delivery, potential 
risk for integration into the genome, toxicity and lower 





Development of the mRNA vaccines is currently based 
on two different strategies: (1) Non-replicating mRNA-
based vaccines encode antigen of interest and contain 5’ 
and 3’ untranslated regions (UTRs) or (2) virally 
derived, self-amplifying RNAs that encode not only the 
antigen but also the viral replication machinery that 
enables intracellular RNA amplification and abundant 
protein expression.121 All RNA vaccines require 
appropriate delivery systems due to unmodified naked 
mRNA being rapidly digested by ribonucleases and 
innate immune response.122 Therefore, candidate SARS-
CoV-2 mRNA vaccines are based on the use of liquid 
nanoparticles as a stabilizer. Several candidate vaccines 
of this type are in clinical trials, most importantly 
mRNA-1273 candidate vaccine that codes for the S 
protein. If approved, mRNA-based vaccine would be the 





Subunit or protein-based vaccines are composed of 
highly purified antigens, either synthetic peptides or 
recombinant proteins used to generate a protective 
immune response.123, 124 Candidate subunit SARS-CoV-
2 that are currently evaluated are based on the full-length 
spike (S) protein, receptor-binding domain (RBD), non-
RBD S protein fragments and non-S structural 
proteins.125 Since highly purified proteins in subunit 
vaccines are usually not inherently immunogenic, 
carefully formulated adjuvants need to be used to ensure 
their immunogenicity. Recombinant S-trimeric SARS-
CoV-2 protein candidate vaccine developed by the 
University of Queensland uses “molecular clamp” 
transformative technology that is based on the synthesis 
of viral surface proteins and their subsequent 
“clamping” in a pre-fusion form. Alternatively, NVX-
CoV2373 vaccine candidate is based on Matrix-M 
adjuvant along a full-length SARS-CoV-2 spike 




Viral vector vaccines 
Vaccines based on non-replicating or replicating viral 
vectors exhibit excellent immunogenicity and are able to 
induce both humoral and cellular specific immune 
responses. The development of SARS-CoV-2 candidate 
vaccines of this type is mainly based on non-replicating 
adenovirus-based vectors113 due to high 
immunogenicity, possibility of administration via oral or 
nasal mucosa and safety (absence of integration into host 
cell genome).122 However, high prevalence of 
neutralizing antibodies specific for adenoviruses in the 
population can have a negative impact on the long-term 




Live-attenuated vaccines have a long history of success 
and are the most frequently used vaccines in humans.128 
They are usually produced by a series of cultivation of 
the microorganism under suboptimal conditions or via 
successive passages in cell cultures that lead to the 
attenuation of virulence while preserving the 
immunogenic potential. This existing infrastructure is a 
big advantage for further development of SARS-CoV-2 
vaccine.129 Attenuated vaccines are also more efficient 
than other platforms in providing a long-lasting 
protective immunity since they persist for longer period 
of time, present the complete array of viral antigens to 
the immune system and deliver antigens to the 
appropriate cell compartments to produce proteins for 
efficient MHC I class presentation and generating a T 
cell response.118 The main problem in the application of 
attenuated vaccines is the possibility of reverting to the 
wild-type virulence.130 Therefore, the risk of revertants 
makes attenuated vaccines inappropriate for infants, 
immunocompromised or elderly individuals.118  
Besides, creating infectious clones takes more time 
because of their large genome size, requirement for 
dedicated biosafety level facilities and the need for 




Inactivated virus vaccines or whole killed virus (WKV) 
vaccines consist of pathogens that are no longer able to 
infect and replicate, but they have retained their ability 
to act as immunogens.118 Pathogens are usually 
inactivated physically or chemically (e.g. formaldehyde 
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or radiation)115, like in a case of the SARS-CoV-2 
clinical candidate CoronaVac from Sinovac Biotech 
Ltd. (formerly PiCoVacc) that used β-propriolactone to 
inhibit viral membrane fusion in a dose-dependent 
manner.131 Inactivated vaccines represent an attractive 
solution for SARS-CoV-2 vaccine development, due to 
their previous successful use, excellent safety profiles, 
simple formulation (no need for adjuvants) and large-
scale manufacturing infrastructure.114 Moreover, by 
exposing the same epitopes which a virus would have 
otherwise presented, these vaccines are very good at 
eliciting strong immune responses.118 Vaccine 
candidates of this type also displayed a good cross-
neutralization to different SARS-CoV-2 strains.131 
However, this technology has several limitations. 
Beside the main issue of raising biosafety concerns due 
to the risk of vaccine preparations containing the 
infectious virus, in vivo experiments with a candidate 
SARS-CoV inactivated vaccine in mice caused a Th2-




Virus-like particle (VLP) vaccines 
Virus-like particles (VLPs) are macromolecular 
complexes that resemble the structure of the virus but 
lack its genetic material, enabling them to mimic the 
native structure of viruses without being infective.132 
These features make VLP-vaccines excellent potential 
candidates for the development of safe and effective 
SARS-CoV-2 vaccines which can efficiently stimulate 
innate and adaptive immune responses.123 VLP-based 
vaccines have mainly been designed to target B-cells 
and induce strong antibody responses following the 
activation of CD4+ T-cells and antigen presentation by 
MHC class II molecules.133 In addition, VLP-based 
vaccines also enable MHC class I-mediated antigen 
presentation and activation of antigen-specific CD8+ T-
cells.133   
Bacterial, insect, yeast and mammalian cells expression 
systems have been widely used in the production of 
VLPs.123 However, candidate vaccine from Medicago 
Inc., as the only VLP vaccine in SARS-CoV-2 clinical 
evaluation, is based on a plant-derived system.113 An 
attractive feature of this type of transient expression 
system, which is based on deconstructed viral vectors 
and Nicotiana benthamiana as a host, is that it can allow 
for immediate exploitation of plants as efficient 
biofactories with rapid and large production of 
injectable vaccines.133 Still, VLPs as a preventive 
vaccine have some considerable problems, such as viral 
mutations that might allow the virus to evade antibody-
mediated neutralization.123 Plant-based vaccines with 
transient nuclear genome transformation also have other 
drawbacks; they require purification of the antigen to 
eliminate toxic compounds from the host (e.g., 
alkaloids), as well as bacterial residues such as 
endotoxins coming from Agrobacterium-mediated 
delivery of viral vectors.133 
CONCLUSION 
SARS-CoV-2 infection and COVID-19 disease are 
likely to remain an unprecedented challenge on the 
global level for an unknown period of time. Further 
research on the molecular features of the virus, its origin 
and underlying pathogenesis of the disease will 
contribute to the development of novel therapeutic 
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